Citadel Advisors
APTO

Citadel Advisors’s Aptose Biosciences, Inc. APTO Stock Holding History

Citadel Advisors’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-26
Closed -$7.55K – 15668
2023
Q1 		$7.55K Sell
26
-32
-55% -$9.29K ﹤0.01% 13712
2022
Q4 		$15.2K Buy
58
+3
+5% +$806 ﹤0.01% 13344
2022
Q3 		$15K Sell
55
-63
-53% -$21.7K ﹤0.01% 12170
2022
Q2 		$39K Buy
118
+18
+18% +$8.61K ﹤0.01% 12084
2022
Q1 		$61K Buy
100
+54
+117% +$29.9K ﹤0.01% 12670
2021
Q4 		$28K Sell
46
-28
-38% -$26.3K ﹤0.01% 13503
2021
Q3 		$73K Sell
74
-17
-19% -$21.3K ﹤0.01% 13134
2021
Q2 		$136K Sell
91
-145
-61% -$316K ﹤0.01% 12608
2021
Q1 		$635K Buy
236
+101
+75% +$200K ﹤0.01% 9160
2020
Q4 		$265K Buy
135
+3
+2% +$7.05K ﹤0.01% 9279
2020
Q3 		$358K Buy
132
+22
+20% +$54.9K ﹤0.01% 7843
2020
Q2 		$312K Buy
110
+21
+24% +$67.7K ﹤0.01% 7848
2020
Q1 		$239K Buy
89
+39
+78% +$116K ﹤0.01% 7712
2019
Q4 		$127K Buy
+50
New +$65.2K ﹤0.01% 8447
2019
Q2 		– Sell
-51
Closed -$46K – 10065
2019
Q1 		$46K Buy
+51
New +$46.2K ﹤0.01% 8856

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
CSC
Caldwell Sutter Capital Sausalito, California $246M AUM 23.62% 1-Year Est. Return

Citadel Advisors's APTO Position: Q2 2025 in Review

Citadel Advisors sold out of Aptose Biosciences, Inc. (APTO) in Q2 2025, closing a stake of 12,007 shares — an estimated $38K sold.

Citadel Advisors first reported a position in APTO in Q3 2018 and held it in 20 quarters. The position peaked at $9.07M in Q3 2020. 4 funds tracked by Wall St. Rank hold APTO as of Q2 2025.

  • Citadel Advisors reported no remaining Aptose Biosciences, Inc. position as of Q2 2025 after selling out during the quarter.
  • Citadel Advisors sold 12,007 Aptose Biosciences, Inc. shares in Q2 2025, an estimated $38K.
  • Citadel Advisors first reported a position in Aptose Biosciences, Inc. in Q3 2018 and held it in 20 quarters.
  • Citadel Advisors's Aptose Biosciences, Inc. position peaked at $9.07M in Q3 2020.
  • 4 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.